UroGen Pharma (URGN) Other Non-Current Assets (2016 - 2026)
UroGen Pharma's (URGN) quarterly Other Non-Current Assets came in at $7.5 million in Q1 2026, up 1919.68% YoY from $371000.0 in Q1 2025, and up 45.19% on a QoQ basis from $5.2 million in Q4 2025.
UroGen Pharma (URGN) Other Non-Current Assets (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Other Non-Current Assets data on file, last reported at $7.5 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 1919.68% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 1919.68% YoY) and the FY2025 annual result came in at $5.2 million, up 776.23% from the prior year.
- Other Non-Current Assets climbed to $7.5 million in Q1 2026, from $5.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $7.5 million in Q1 2026 to a low of $370000.0 in Q3 2024.
- A 5-year average of $2.5 million and a median of $2.0 million in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 2281.82% — and 2024, when it tumbled 81.95%.
- Tracing URGN's Other Non-Current Assets over 5 years: stood at $2.7 million in 2022, then dropped by 25.62% to $2.0 million in 2023, then slumped by 71.1% to $589000.0 in 2024, then soared by 776.23% to $5.2 million in 2025, then surged by 45.19% to $7.5 million in 2026.
- The last three Other Non-Current Assets figures came in at $7.5 million (Q1 2026), $5.2 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 8.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.76 Mn |
| Mar 31, 2026 | 7.49 Mn |
| Dec 31, 2025 | 5.16 Mn |
| Sep 30, 2025 | 6.76 Mn |
| Jun 30, 2025 | 801,000.00 |
| Mar 31, 2025 | 371,000.00 |
| Dec 31, 2024 | 589,000.00 |
| Sep 30, 2024 | 370,000.00 |
| Jun 30, 2024 | 673,000.00 |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | 2.04 Mn |
| Sep 30, 2023 | 2.05 Mn |
| Jun 30, 2023 | 2.82 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 2.74 Mn |
| Sep 30, 2022 | 2.47 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 1.57 Mn |
| Dec 31, 2021 | 1.31 Mn |
| Sep 30, 2021 | 1.77 Mn |